Tango Therapeutics (NasdaqGM:TNGX) FY Conference Transcript

Summary of Tango Therapeutics FY Conference Call Company Overview - Company: Tango Therapeutics (NasdaqGM:TNGX) - Focus: Small molecule precision oncology targeting novel cancer pathways - Key Programs: Three clinical programs including bopametastat (TNG462), TNG456, and TNG260 [5][8] Key Clinical Programs Bopametastat (TNG462) - Type: MTA cooperative PRMT5 inhibitor - Clinical Data: - Overall response rate of 27% in over 150 patients, compared to 23% for BMS504 [5][6] - Median progression-free survival (PFS) of 6.4 months [5] - In second-line pancreatic cancer, overall response rate of 25% with median PFS of 7.2 months, significantly better than standard chemotherapy (2-3.5 months) [6][14] - In a selective cohort (excluding certain cancers), overall response rate was 49% with median PFS exceeding 9 months [7] - Market Potential: Approximately 60,000 MTAP-deleted cancer patients in the US annually, including 20,000 pancreatic cancer patients [8] TNG456 - Description: Brain-penetrant version of TNG462, targeting glioblastoma (GBM) [7] - Patient Population: 40% of GBM patients are MTAP-deleted, with about 8,000 new cases annually in the US [7] TNG260 - Status: Early proof of concept in non-small cell lung cancer (NSCLC) patients with specific mutations [8] Competitive Landscape - Main Competitor: BMS504, with ongoing studies exploring various dose levels [11] - Differentiators: Bopametastat shows superior safety profile (less GI toxicity, less rash) and has a defined dose for pivotal studies [11][13] - Strategic Positioning: Tango is the first PRMT5 inhibitor to combine with KRAS inhibitors, enhancing its competitive edge [13] Clinical Trial Design and Strategy - Upcoming Pivotal Study: - Focused on second-line pancreatic cancer, comparing bopametastat to standard chemotherapy [27] - Approximately 300 patients, utilizing a hierarchical design for statistical efficiency [27][28] - FDA Alignment: Successfully completed end-of-phase meeting with FDA, confirming trial design [29] Market Dynamics - Emerging Treatments: KRAS inhibitors like Diraxonracib expected to gain approval, with Tango positioning itself for second-line treatment [24] - Combination Strategies: Plans to explore combinations of bopametastat with Diraxonracib in both pancreatic and NSCLC [34] Financial Outlook - Cash Runway: Sufficient funds to support operations through 2028, covering pivotal studies and ongoing clinical trials [47] Key Takeaways - Focus for 2026: Execution of pivotal studies and advancing combination therapies with Revolution Medicines [47] - Long-term Vision: Aim to establish a strong position in both second-line and frontline treatment settings for pancreatic cancer and other malignancies [25][47]